Identifying immunohistochemical biomarkers panel for non-small cell lung cancer in optimizing treatment and forecasting efficacy
Abstract Background Chemotherapy and immunotherapy for non-small-cell lung cancer (NSCLC) are gaining momentum. However, its long-term efficacy remains limited to only a small fraction of patients. Hence, it is crucial to identify reliable immunohistochemical biomarkers to facilitate the formulation...
Saved in:
| Main Authors: | Xiaoya Zhang, Junhong Meng, Mingyue Gao, Cheng Gong, Cong Peng, Duxian Liu |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-11-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-024-13184-8 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
<i>NALCN</i> Promoter Methylation as a Biomarker for Metastatic Risk in a Cohort of Non-Small Cell Lung Cancer Patients
by: Eleni Thanou, et al.
Published: (2024-11-01) -
CTSG is a prognostic marker involved in immune infiltration and inhibits tumor progression though the MAPK signaling pathway in non-small cell lung cancer
by: Qian Dai, et al.
Published: (2024-12-01) -
Prognostic and Predictive Biomarkers of Oligometastatic NSCLC: New Insights and Clinical Applications
by: Mandy Jongbloed, MD, et al.
Published: (2024-12-01) -
Unmasking The Hidden Clues: Shedding Light On The Potential Of Novel Biomarkers In Endometrial Cancer, Comparing RT-Qpcr And Immunohistochemical Analysis In Clinical Specimens
by: Sampana Fatima, et al.
Published: (2025-01-01) -
Osteopontin is a prognostic biomarker in non-small cell lung cancer
by: Ane Kongsgaard, et al.
Published: (2013-11-01)